These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34303664)

  • 1. Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
    Faria J; Gerritsen KGF; Nguyen TQ; Mihaila SM; Masereeuw R
    Eur J Pharmacol; 2021 Oct; 908():174378. PubMed ID: 34303664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.
    Dai ZC; Chen JX; Zou R; Liang XB; Tang JX; Yao CW
    Front Immunol; 2023; 14():1213473. PubMed ID: 37809091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt apoptotic response to high glucose in SGLT-expressing renal cells.
    Nilsson LM; Zhang L; Bondar A; Svensson D; Wernerson A; Brismar H; Scott L; Aperia A
    Am J Physiol Renal Physiol; 2019 May; 316(5):F1078-F1089. PubMed ID: 30864838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney Proximal Tubule GLUT2-More than Meets the Eye.
    Ahmad M; Abramovich I; Agranovich B; Nemirovski A; Gottlieb E; Hinden L; Tam J
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
    Toto RD
    Nephron; 2017; 137(1):64-67. PubMed ID: 28743130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
    Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
    Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
    Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
    Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
    Karalliedde J; Winocour P; Chowdhury TA; De P; Frankel AH; Montero RM; Pokrajac A; Banerjee D; Dasgupta I; Fogarty D; Sharif A; Wahba M; Mark PB; Zac-Varghese S; Patel DC; Bain SC
    Diabet Med; 2022 Apr; 39(4):e14769. PubMed ID: 35080257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
    Gill A; Gray SP; Jandeleit-Dahm KA; Watson AMD
    Curr Diabetes Rev; 2019; 15(5):349-356. PubMed ID: 29663893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.